Max Healthcare Institute Ltd
NSE:MAXHEALTH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
601.65
1 079.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Max Healthcare Institute Ltd
Earnings Call Analysis
Q3-2024 Analysis
Max Healthcare Institute Ltd
Over the past quarter, the company has experienced an exceptional performance, marking the 13th consecutive quarter of year-on-year growth. The network occupancy has been stable at 73% with an institutional bed share slightly increasing to 29.5% from last year's 29.4% and addressing a marginal 1% dip in occupied bed days year-on-year.
There has been a significant 15% year-on-year growth in average revenue per occupied bed (ARPOB), with the current figure standing at INR 76,800. This gain is bolstered by network gross revenue climbing by 14% year-on-year to INR 1,779 crores. The network's operating EBITDA rose by 12% year-on-year and annualized EBITDA per bed hit a peak, demonstrating a 13% year-on-year increase. However, a quarter-on-quarter decline of 3% in revenue and a 5% decrease in operating EBITDA was observed, mainly due to seasonal impacts. Operating EBITDA margins stood strong at 27.9% for the quarter. The company posted a profit after tax of INR 338 crores, reflecting a robust bottom-line performance.
The company's net cash position has seen a remarkable improvement, reaching INR 1,295 crores at the end of December 2023 compared to INR 372 crores in the previous year. Additionally, the company has committed to its community support, having served around 36,700 outpatients and 1,250 inpatients from economically weaker sections of the society.
The non-core business segment is showing dynamic growth. Max Lab, the non-cash vertical, has extended its operations to 41 cities, while Max reported a strong top-line growth of 24% year-on-year and 5% quarter-on-quarter, indicating a diversified and growing business model. The company has ongoing expansion projects in various locations like Dwarka, Nanavati, and Gurgaon that promise future increases in bed capacity and operational scale.
For the nine-month period, network gross revenue showed a year-on-year increase of 16%. Operational efficiencies and expansion led to a 17% year-on-year growth in Network operating EBITDA to INR 1,404 crores, and a 15% increment in EBITDA per bed. The company also generated free cash flow of INR 924 crores and has strategically deployed INR 265 crores towards ongoing expansion projects.
After a weekly impact due to price adjustments in December, the company sustained a run rate with a net gain of INR 14 crores for the quarter. The EBITDA for this quarter could see an increase of INR 1.5 crores if tariff adjustments were excluded. Although the tariff for the bed city was reduced by approximately 50%, from INR 22,000 to around INR 11,000, the company is optimistic and has made representations to reverse what is believed to be an error in the speciality segment.
A notable outcome of ongoing initiatives is a 25% compounded annual growth rate in international business. Even without 'big bang' policy changes, simplifications in medical visa processes and promotion of medical tourism have contributed to this growth. The international business currently contributes to 9.4% of the revenue, which is likely to increase with the overall growth at 14% and international business at 25%.
The company is seeing major developments across the three streams of oncology—surgical, medical, and radiation. Investments in robotics, a better average length of stay, and improved outcomes, particularly in surgical oncology, have led to the doubling of contributions over the last year. Noteworthy progress is also observed in radiation and medical oncology, with a forward-looking approach on immunotherapy, despite its current high costs.
A key area for potential growth identified is the expansion of operational bed capacity. Currently, at 285 operational beds, there is an opportunity to scale up to 550 beds in a recently discussed facility which will undergo renovation and equipment upgrades. This expansion is projected to materialize within a couple of years.
You don't have any saved screeners yet
Ladies and gentlemen, good day, and welcome to Max Healthcare Institute Limited's earnings conference call. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Suraj Digawalekar from CDR India. Thank you, and over to you, Suraj.
Thank you, Michel. Good morning, everyone, and thank you for joining us on Max Healthcare's Q3 and 9M FY '24 Earnings Conference Call. We have with us Mr. Abhay Soi, Chairman and Managing Director; Mr. Yogesh Sareen, Senior Director and Chief Financial Officer; and Mr. Keshav Gupta, Senior Director, Growth, M&A and Business Planning. We will begin the call with opening remarks from the management, following which, we will have the forum open for an interactive Q&A session.
Before we start, I would like to point out that some statements made in today's call may be forward-looking in nature, and a disclaimer to this effect has been included in the earnings presentation shared with you earlier.
I would now like to invite Abhay to make his opening remarks.
A very good morning to everyone, and a warm welcome to Max Healthcare's earnings call for the third quarter.
This quarter has been exceptional for us primarily for 2 reasons: First is the presence of 13th consecutive quarter of year-on-year growth. We recorded a healthy increase in network revenue and EBITDA by 14% and 12%, respectively. And more importantly, we managed to grow ARPOB and EBITDA per bed sequentially despite Q3 being a seasonally lean quarter.
Second, this quarter, Max into Central UP which is one of the most populous and fast-growing states in the country through the acquisition of 550 beds Sahara Hospital in Lotna. This acquisition will fortify our presence in Northern India and is in line with the articulated strategy of entering new markets where peers have demonstrated success. We expect to contribute the transaction in Q4 and are ready with a plan of action to improve the infrastructure, augment the operational bed capacity, add to the existing medical talent as well as integrate the hospitals with the IT systems.
On the clinical front, we have launched the CAR T cell therapy at Max Vaishali in collaboration with ImmunoAct. Also known as a living drug, this groundbreaking therapy is expected to enhance the quality of life for many patients and reflects our continuous endeavor to provide our patients with the latest therapeutic options for cancer treatment.
Now coming to the highlights of Q3 performance. Occupied bed days dipped marginally by around 1% year-on-year due to lower prevalence and spillover of vector-borne diseases in this quarter compared to last year. Average occupancy for the network was 73%. Institutional bed share at 29.5% compared to 29.4% last year and 27.3% in Q2 this year. However, after excluding Max Shalimar Bagh, the overall institutional bed share stood at 27.4% during Q3, and occupied bed days were down by 8% for the segment. Sequential increase institutional bed share was a conscious call taken going to Q3 being a seasonally weak quarter on occupancy.
Average revenue per occupied bed for the quarter improved to INR 76,800, growing by 15% year-on-year and 3% quarter-on-quarter. Year-on-year, improvement was witnessed across all specialties with oncology, neurology and renal sciences being the key drivers. Network gross revenue was around INR 1,779 crores compared to INR 1,559 crore in Q3 last year and INR 1,827 crores in the previous quarter. This reflects an increase of 14% year-on-year, driven mainly by growth in ARPOB.
Revenue declined by 3% quarter-on-quarter due to festive season in Q3 and vector-borne diseases that had jump in admissions during Q2. Revenue from international business grew significantly by 25% year-on-year. This payer channel now accounts for around 9.5% -- 9.4% of the total revenue from our hospitals.
Network operating EBITDA stood at INR 471 crores, reflecting a growth of 12% year-on-year and a decline of 5% quarter-on-quarter. Most importantly, annualized EBITDA per bed rose to the highest level of INR 75.6 lakhs, clocking a growth of 13% year-on-year and 1% quarter-on-quarter. Operating EBITDA margin stood at 27.9% for the quarter. Year-over-year growth in EBITDA was impacted due to additional charge of INR 25 crores, driven by movement in provision for doubtful debts, reversal of provision for old phantom stock option plan in Q3 last year after launch of the new ESOP scheme in November 2022, GST impact of variable management fees and onetime litigation cost.
At Shalimar Bagh, where we added 122 beds, recorded year-on-year growth of 36% and 42% in its revenue and EBITDA, respectively, with an average occupancy of 74%. Profit after tax was INR 338 crores versus INR 269 crores in Q3 last year and at the same level as in the previous quarter. Year-on-year improvement of 86% was primarily attributable to flow-through of improved EBITDA and lower finance costs.
Free cash flow from operations generated this quarter amounted to INR 226 crores after additional outlay of INR 40 crores for purchase of robotic systems at 4 of our hospitals. Of this, INR 137 crores was deployed towards the ongoing capacity expansion projects and INR 97 crores was distributed as dividend. Net cash position improved to INR 1,295 crores at the end of December 2023 compared to INR 372 crores same time last year.
Continuing our efforts to support the local communities, we treated approximately 36,700 patients in OPD and 1,250 patients in IPD from economically weaker section of society absolutely entirely free of charge.
Both our strategic business units continue to maintain the growth momentum. Max reported a top line of INR 44 crores, reflecting a strong growth of 24% year-on-year and 5% quarter-on-quarter. We continue to witness good demand for the SBU services as demonstrated by over 50 [ 53 ] transactions by patients in the last 1 year in our home care service alone. Max Lab, the non-cash vertical, now offers its services in 41 cities and has a network of over 1,000 collection centers and active partners. This SBU reported a gross revenue of INR 34 crores, reflecting a growth of 20% year-on-year.
On the status of our expansion projects, Dwarka, 4,300 beds. As informed previously, application for occupancy certificate was submitted in October, finishing under progress. In the meanwhile, we already have the unit head and all other key functional heads in place. We have commenced hiring for middle-level staff as well.
For the 329 beds at Nanavati, basement and ground level structures have just been completed, while steel fabrication above ground flow has begun. The project continues to be largely on schedule. [ For 300 ] beds at sector 56 Gurgaon. Approval for structural buying has been received in the first week of Jan, and RCC works have already commenced.
490 beds at Mohali design development is under finalization in the meanwhile, the base RAF concrete activities have started. Both of these are largely into [indiscernible]. 350 beds at Max Market at Socket Complex The transplantation works underway with 159 trees transplanted and balance 316 trees in process for transplantation. As per plan, existing structures have been demolished, and shoring work for sewage and water treatment plants is going on. Barring the initial delay of 6, 7 months, the project was on schedule now.
For 300 beds in Max Vikrant at [indiscernible] complex, the building plans have been resubmitted to the corporation post their initial review. And what tends to wage infrastructure. There's some payments should be made that have been paid and that is being connected. Tender documents are underway for floating to contractors. Applications for NOC by forest department has also been filed.
For 250 beds, as per the [indiscernible], the fire department issued NOC for the building plants in Nupur Corporation approval is in progress. All projects continue to be largely constituted despite some disturbances linked to enforcement of draft, which is a graded response action plan in NCR to combat air quality issue.
Finally, moving on the overview -- on to the overview of the company's performance for the 9 months ended December 31, 2023. Network gross revenue stood at INR 5,325 crores, reflecting a growth of 16% year-on-year. Network operating EBITDA grew by 17% year-on-year to INR 1,404 crores. Increased ARPOB, improved case mix and augmentation of network be capacity by 146 beds translated into improvement in EBITDA per bed by 15% to INR 73.8 lakhs per bed. During the 9 months, we generated INR 924 crores of free cash flow from operations after interest, working capital changes and routine CapEx, of which INR 265 crores has been deployed towards ongoing expansion projects and INR 97 crores was distributed as dividend.
With this, we open the floor for questions and answers.
[Operator Instructions] The first question is from the line of Damayanti Kerai from HSBC Securities and Capital Markets.
My first question is on the institutional tariff division, which we saw in the month of December. So you mentioned there will be net loss of around INR 6 crores annually. Is it, like, ongoing? And just want to understand if this event has happened, the net gain, which you mentioned for the third quarter, INR 14 crores, should we have added this INR 6 crores back with INR 14 crores plus INR 6 crores, if the prices were not declining?
No. So basically INR 14 crores is for the quarter, right? So that's the run rate. That run rate also has the -- some impact of the price reason, which happened in the month of December, right? So around 1 week impact has already come in there. So INR 6 crores number is annual number, INR 14 crore number is a quarterly number. So now you can do what you want to do.
Okay. And...
On the question if you didn't have the INR 6 crores, then you would add it back to this EBITDA. You will add it to this EBITDA for this quarter, INR 1.5 crores.
INR 1.5 crores. Okay. And do you expect any further revision in tariffs for this channel? Or do you think like now broadly done and we might not see any additional...
We're expecting revenue in tariffs, even the specialty thing, we think it will be alone. We made representations. So we have box with them to revise.
Okay. So for the income, right, and then that should be maybe [indiscernible] to add [indiscernible]
I expect this -- even the specialty should get revised in the way. We believe it was an error.
Okay. Okay. That 10,000 is going to something [ 11,500 ], right? .
No. So Damayanti, the tariff for the bed city has come down by around 50%, right, from INR 22,000 to INR 11,000 something. So it is 50% reduction. And that major impact because, as you know, we [indiscernible] to be a bit the share of revenue for us. And so that was a INR 10 crore impact on the -- for the [indiscernible]. [indiscernible] by around INR 4 crores. So net impact is INR 6 cores, right? And that's all annualized numbers I'm talking.
Okay. Understood. And a few quarters back, you talked about this India initiative, which should be giving goods to your international business. So any update on that front or any discussion ongoing around that initiative, which...
We haven't done a big bang as it was expected. What they've done is there's a lot of movement in the MPCs and so on and so forth. The fast-tracking medical visas. They've taken off those policies or reporting to police stations. They are bringing down -- they brought down the price for medical reasons and heavily promoting it globally. -- is the company to India participating in various medical tourism, for and so on. And this is -- I mean right now it's leading to a trickle effect. I mean trickle effect meaning its growth of 25% and some not, given the sales opportunity, it's not exponential, it's still incremental, right, at a 25% CAGR on this.
Okay. And from Max perspective, right now, it's around 9.4% revenue contributed to international paging. How much it can go up in, say, next 3 years even if we don't hear any big changes by the government and these kind of small or I'll say [indiscernible]
[indiscernible] 25% figure. I mean, it's not this quarter. Last quarter was the same. The previous quarter was the same. I think last 5 quarters has been at this, and I don't really see it abating.
Yes. So Damayanti, if the overall growth is 14% and the -- and this generally is doing 25%, our business shares should go up, right, going forward.
Yes. Got it. And my last question is, as you mentioned, oncology is a big focus for you and you have been investing in this segment. So which are the key growth opportunities as for Max's focus? And then what kind of expectation you have from this segment in terms of addition to your hospital revenues over the next few years?
So I think they are within the 3 streams really of oncology. We've got surgical, we've got medical, we've got radiation. I think there are various sort of innovations have been within the 3 itself. We have very more and more robotics. So it's a better ALOS. It's better outcomes. And -- but at the same time, the percentage margins are lower, but absolute value to hospitals is more because in terms of the EBITDA per bed that you're able to derive from that is higher than what you do for a normal oncology strategy. And that number sort of doubled over last year. So I mean we have seen major growth in [indiscernible].
Now similarly, if you look at radiation, okay, from a typical 1 and 2 now various kinds of things and so on and so forth. But -- and so there have been other kind of innovation within the medical oncology as well. And now we're also looking at immunotherapy. Like we mentioned that we started [indiscernible] so this is another stream altogether, which is some segment of chemo, but nevertheless. And globally, I think it's a little expensive right now, and we are seeing prices come down. So the [indiscernible] of that is going to be a lot more. But that's what the world is moving towards in oncology, right, is immunotherapy now.
The next question is from the line of Harith Ahamed from [ Evander Spark. ]
The first question was on the recently acquired Max hospital. So currently, we have around [ 250 ] operational beds there and you talked about a capacity of 550 beds. So can you share your thought process in terms of -- operational bed count, higher more [indiscernible] capacity bed count?
So what is -- one is the amount of area which has already been constructed. It's about close to 1 million square feet. Number of beds operational are 285. So there's obviously an opportunity. I mean we can ramp up to the 550 as tenders within this. The facility has been ignored for a while. So I think we are going to be changing the equipment, and we have to sort of redo the infrastructure. When I say redo the infrastructure, basically, internal renovation which needs to be done. This is a brand-new building made by LNP contractor construction started in, I think, 2010, 2011. So it's not an old structure, but of course, you need to kind of renovate it.
So I think within a couple of years, we should be at that 550 mark -- number of bed mark in perhaps a little before that. You have do -- keep in mind that we are going to be closing the transaction. We're not in the saddle as yet. The majority of the CPs as per schedule have been done. The rest are also on schedule. But until the last one is done, that's when we will share more details about it.
Okay. And my second question is around the time lines of some of the upcoming hospitals. So apart from [indiscernible], you guided for 300 hospitals to 400 in commission in the next 12 to 15 months [indiscernible]. But when I look at the CapEx project, CapEx, specifically, we are tracking a bit lower versus our guidance of INR 900 crores for FY '24. We had around INR 300 crores 9 month FY '24. So are we still expecting these 3 hospitals even though get commissioned in FY '25?
Absolutely. So Dwarka, which is getting commissioned, do keep in mind, it is off our books because this was an asset-light model, right? The developer is investing the money, whereas we are bringing the medical equipment in place. So we have not -- the entire 300-bed hospital is not signed. And the hospital is complete in all respects. I mean, we are right now in the phase where we are doing the finishes to the hospital and sort of whatever medical equipment that we've brought in, we are implementing it.
It's not going to be a major CapEx for us going forward either as far as Dwarka is concerned. It was never meant to be because it's asset-light. We're essentially paying a lease amount for that, right? I'd say, a yield of, I think, 6%, 7.5% or something like that. That's a 60-year contract for the land building, a finished land and building of 300 beds.
As far as Nanavati is concerned, we've come to -- we've already built our 3 basements, and we've come to ground level. Now this is where things start speeding up. Do keep in mind, the first part of construction is real super structure. It doesn't really cost that much money. I mean if we were to -- it typically costs INR 1,500 to INR 1,800 a square foot. So if you're building even 1 million square feet, then you would have spent INR 120 crores just doing the construction, right, of this superstructure.
Real money is spent at the latter half part of it. When you go into finishing, when you go into interiors and so on and so forth, when you bring into the high side, low side equipment lifts and so on and so forth, air conditioning and all of that. So I think everything, as far as the payment is concerned and this thing is considered, is on schedule. So I would not look at that -- the payment is always lumpy towards the end. So I will not look at that as a surrogate for completion of project, at least at this stage.
Okay. Perfect. Last one is on [indiscernible] Certainly broad question. When I look at the complex currently, [indiscernible] and have on 800 beds there. And in the next 3 years, we're looking to add close to 800, 900 beds, and we have plans to add maybe 500, 600 beds [indiscernible] FY '28. So that's almost 2,000 beds in almost 6 location. So it's kind of on hold off, so can you share your thought process behind such a large number of beds at a single location? How are we going to differentiate it? And how do we plan to whatever strategy to ensure that there is no overcapacity situation in that [indiscernible]?
So firstly, on the Saket complex is pretty much trite main flagship as you're aware, right? I mean -- so we are pretty much tearing at the scenes as far as Saket is concerned. We've added -- in a place like Shalimar Bagh, we added about 40%, 50% more capacity, which was then what was present there. And within the first month or so, our capacity occupancy went down to -- went up by about 80%, 85%. My belief is that -- and we have collectively very strongly believed that if we were -- so this 1,000 beds or 800 beds or 900 beds that you're speaking about, this is not coming all together, as you may appreciate.
First, the 300-odd beds come into play. [indiscernible] 40% capacity. On top of this -- on top of the current sort of capacity of 770, 800 beds that we have, that will be more or less instantly taken up, right? I mean you're going to have a very quick sort of occupancy of the first 300 beds. And very soon, let's say, very, very soon thereafter, you want to be ready for the additional capacity. Like in Shalimar Bagh where you run out of capacity, right? So even though you're going to have the same situation. So you'll require the next 300 beds. And so what you can't do is start instructing 300 beds then and take another 3 years. You will need that 300 beds once these first 300 beds are occupied. And that really speaks for the first year. Now then come to the last phase of, let's say, another 300 beds thereafter, right? Now that only when the 300 beds, the second 300 beds get occupied. Okay, if you look at the last piece. We will make superstructure, which I again mentioned, it's not a major cost, okay? This is if things are going as per plan. But you can always call, you can always -- at the last 300 beds, you can always say, look, I'm completing this superstructure and the external of the I'm not putting it up if you see any sort of softness of demand. Our belief is this is a trajectory that we have over the next 5 to 6 years, you will be able to occupy all of those beds. But it does not mean that after Phase 1, if you -- let's say, for some reason, okay, and which is beyond me, to be honest, the first 300 beds don't get occupied, you don't have to put out the next 300 beds. You don't have to build the next 300 beds.
Okay.
And also, this is a base case. Do keep in mind, at various stages in various places, the default options. You don't build that. It's a hospital. We can't have a disruptive process. The infrastructure, the superstructures cost [indiscernible] Again, you're looking to look at [indiscernible] [ INR 120 crores, INR 150 crores, INR 180 crores. ] I mean that's [indiscernible]. I mean, that's what it, right? It's not more than that.
Also, FY '28 onwards is a placeholder, right? That's a potential. We are not investing anything for the FY '28 [indiscernible]. We don't even have the approvals on the Board to spend on that, right? So that's only reflects that we then build those money at more on those land pieces.
I mean, theoretically, in -- now if you look at the 27 acres of land, you can build another 3,500 or 4,000 beds potentially [indiscernible] 20 years [indiscernible] infinity does not mean we will build 3,500 beds there.
The next question is from the line of Neha Manpuria from Bank of America.
On the [indiscernible] acquisition, how should we think about narrowing the operating performance gap that is there between, let's say, what Max is doing now in -- particularly since will continue to ramp up that debt. Is it fair to assume that we need to get to that full [ 5 50 ] to narrow that gap meaningfully and it would happen over a period of time?
So we are quite confident that in the next -- within a couple of years, we will be able to get all of these beds, okay, into sort of conditions or perhaps better than what we have with any another hospital and be able to catch up with our peers as well, and you know our peers over there, okay, both in terms of -- on every financial parameter there. If not, exceed them.
Okay. But this would take a few years in your view?
No. So [indiscernible] it should be -- it should be done within 2 years.
Got it. And second, again, just extending the -- question to a more broader strategy. Now that we have this -- we'll have 500 beds. I know you said you have land for adding more capacity. But do you see that as a market where you can have, let's say, multiple facilities? And is that something that you're looking that this could be a third hub outside of, let's say, the current 2 hubs that you have?
Absolutely. So I look at now just to find certainly many more health care facilities. In UP's population is the size of Europe. And literally, it's got 1.5 corporate hospitals over there right now as we speak, beside hopefully, when we get in with some 2.5. But if you -- I don't know if you've been there recently, but the level of development, connectivity, the road, the infrastructure, the kind of focus is that the city is getting -- I mean I think it will be a metro very soon and just the scale of infrastructure, the airport and so on and so forth.
And the connectivity with other areas backward years is on both from rail, air, road, every which means. On top of that, the government itself has a very, very strong program that the Chief Minister fund over there actually pays hospital tariffs for patients. So I mean, if you imagine the entire population where the chief minister fund is paying hospital tariffs for patients at the hospitals. Not the CGS rate, not some low rates or whatever else. I mean I think on multiple trends, more than 1 hospital.
And this would be through M&A, do you think? Or will just make it happen faster? Or would you choose a more organic approach of expanding into that market?
Neha, unfortunately, I don't think there are too many M&A opportunities or existing hospitals in Lotna. They are far and few. I mean if we are able to get lucky again, like we've got in this case, of course, we look at an acquisition first because that's a faster in. But if not, when we look at inorganic -- organic growth as well, build out.
Right. And my second question is on Dwarka. I think you mentioned that the unit had key function heads have already been appointed. Is that cost already sitting in the quarter? Because if I look at our direct...
That's right, that's right.
Haven't increased as much in the last 3 quarters. So [indiscernible]...
Yes. So that cost is sitting. And also certain doctors have been sort of onboarded and that cost may also be sitting in this quarter.
Okay. Okay. So as we commission this and phase it out, you should start seeing that contribute to EBITDA pretty quickly.
That's right. Because the cost is already incurred. I mean not a -- I mean the large -- the biggest cost is always the nonmedical personnel, right? I mean it's a -- I've always mentioned that 23% or 24% of the overall revenue. In fact, for a new hospital, it's higher because revenues are lower. And that is typically brought in large -- I mean, that's really the significant amount of heads that you have is under that cost, and that comes in closer to hospital commissioning, which is now, I think, very shortly should have that hospital up and running.
And for breakeven in Dwarka, is 12 months, 18 months a good time frame to assume?
Well, that's the textbook. We hope we can grow it faster. That's textbook.
[Operator Instructions] The next question is from the line of Kunal Dhamesha from Macquarie.
So first one on the institutional rates. I think there has been some revision, of course, some revision downward. But when we sum it up, let's say, for the first 9 months, what could have been the ARPOB impact in that channel? I think for the first half, we had suggested the institutional ARPOB has grown at 28% year-on-year. If you could provide that number for first 9 months?
I think my knowledge, I think, go by that it's been up on everything except for one item which went out, which [indiscernible] made a presentation. What is the...
Kunal, you have the number with you. [indiscernible] the price increase is INR 14 crores per quarter, and there's a store annualized impact of this. So that means the net impact is INR 15 crores on the institutional business in terms of price. So if you then divided with the numbers, we will get the increasing the ARPOB, right?
Which will be what? The central is [indiscernible].
Which will be 3%, 4%.
3%, 4%?
Yes. On that.
So overall ARPOB, overall ARPOB is less than 1%, let's say 1% in the overall ARPOB.
But last quarter, you had said that institutional ARPOB increased by 28%.
Institutional ARPOB, not -- overall impact is less than 1%.
But if our institutional revenue is down 18% and that revenue is growing at 30%, then the weighted average impact should be around 5%, right?
No. So then, let's not confuse ourselves. First of all, the total impact is INR 50 crore, right, as you stand today on the overall top line which is less than 1%, right? Our top line last year was around INR 6,600. So if you take INR 50 crores, that will be less than 1%. So that's one. On the overall ARPOB...
[indiscernible] this year was 17%.
Yes, yes. So let's say now if you talk about the ARPOB of the institute, you said, then we do around INR 200 crores of business in a year for institutional. And this is a INR 50 crore impact on that, right? So 4%, around 3.5%, 4%, right. Yes. Is that clear, Kunal?
Yes, this is clear, but last quarter then, I don't know.
Last quarter, growth in ARPOB is not only price, right? We never said that it's all because of price. There's been a growth in institutional ARPOB, but we haven't said it's by price. It still the growth, right? Even this year -- this quarter, if you see compare -- the price impact is only 4% that. Rest is the business mix. Also, you should understand that when the onco goes up, we can go up. When the [indiscernible] goes up, the ARPOB improves, right? And a large model, we've been focusing even with institutional on the higher-end specialty. That's the outcome.
Sure, sure. And the 15% ARPOB growth that we have seen, I think first half was also 13%, 14%. But going into next year, what is -- is that kind of would be thinking about in terms of ARPOB growth? Because clearly, these numbers are, in my view, at least, it's above the historical trend line. And we have been doing high-end surgeries, robotic surgeries. Do you think that this can sustain this run rate of ARPOB for the next 2 to 3 years?
Well, you're the analyst, you have to tell me. I mean, I keep asking the same question. Is there any onetime price change which has led to this? I mean, in my mind, there are a few factors which have led to higher ARPOBs. One is more higher-end surgeries. Second is international patients. Third is proliferation of insurance and so on. These are things which are leading to higher ARPOB. And if any of these is non secular, then your guess is as good as mine. My belief has been that they see pretty secular and that should lead into next year as well. None of this is based on one end.
Yes. And no, it's not only, right? So you see the competition, the thinks improving in all other hospital chains also.
There is a nonsecular trend which has been propelling it. But I mean, I'm at a loss of what it would be.
And sir, one logistic question on the international patient bed share this quarter. If you can share that.
So it will be around [ 5 28%. ]
5 28%. Okay. I have more questions and [indiscernible]
The next question is from the line of Ankit Shah from Canara Robeco AMC.
So my question has been important to the Dwarka additions. So you mentioned that some of the costs have started coming, but a major push in the nonmedical cost will come going forward. So can you give some sense of like how much of that nonmedical cost would be of the total cost? And also, you had mentioned earlier that total losses initially in this is not actually INR 30 crore to INR 40 crore. So can you give some sense on how this -- I mean, would this be completely front-ended or costs come in a stepwise fashion [indiscernible] so it will be more [indiscernible]
No, I think it will be decrease down, so it will be in a decreasing price. Of course, the first month is more the second month should be sooner and then sort of start peaking down till you break even. Yes. So the textbook, this size of a hospital should have a similar sort of INR 40 crores, INR 50 crores kind of loss that we hope to perform better. And maybe we [indiscernible] hopefully soon.
Okay. So most of this...
I mean it's a little hard to kind of [indiscernible] because as and when the doctors come in, those particular programs kick in, right? I mean certain doctors will be brought in certain to guarantees some others but certain other billings, et cetera. Because to give you that loss figure and actually what's the trajectory of the losses, I need to figure out what the exact revenue figures that would be on that particular month.
Right. But also on the hiring front, I mean, does the hiring happen in one shot for the entire capacity? Or is it -- does it happen as a wise fashion?
No, no. So we are going to be coming up with 160 beds first. And of which, also -- let's say, we want to operate 100-odd beds. And we -- in the first go, we'll be hiring at least 100-odd beds.
Okay. Got it.
Unless we get enough of those kind of clinical programs begin where we start off in 116 beds. So right now, we're only doing this [indiscernible] They'll always, let's say, if there are 20 NOIs, which we have issued to 20 doctors, et cetera, in 2 or 15 of them have joined another 5 in the process. It's in the world, right? So as and when I have it in hand, I know the guys coming and need to certificates and the doctors were in to support it.
The next question is from the line of Tushar Manudhane from Motilal Oswal Financial Services. I'm sorry.
We are not able to hear.
Am I audible now?
Yes, sir.
Yes.
Sir, just on the international patients, I would like to understand the growth maybe for the quarter and as well as for the 9 months, how it could break down into volume and maybe the realization growth? .
The growth is the 25%, I think both on 9 months as well as quarter.
[ But ]
Yes. So the ARPOB has grown by 9% in the quarter. But the bed share is 5.8% and overall spread, right? So it's a INR 150 crore last quarter and INR 157 crores revenue this quarter.
Sure, sure. So and this -- right. So the 9% increase in realization is to do with case mix? Or it's like the similar treatment?
So there's no price element in this. It will basically be a -- We haven't increased the prices. Typically, the price over in transition are linked to these applications, and the debt revive only in the month of April, right?
Sorry, sir...
I said, the price increase for internal patients is tagged with the pricing season self-revision. The self-pay price increase happens in the month of April. So to that extent, there is no price element in this. It is only the mix which is increasing the ARPOB by 9%.
Understood. And secondly, just on the overall operational cost in terms of, let's say, employee cost and other expenses for FY '25 in particular, considering the different new hospitals coming up. So what kind of cost increase one should think about?
No, so we can tell you about the processes on the existing hospitals, which is typically an increment of around 7%. And then if there any additional [indiscernible] there'll be many required. So typical money would be -- fits people to 1 bed, right? So let's say, adding 100 beds to the operational capacity, you should assume that there will be 600 more people. [indiscernible] that time, you can you can really tell you that, right? So I mean, I can't give you the exact number of the dose, et cetera, but I'm just giving you mathematics to really get to the number.
Got it. So effectively trying to understand the -- considering the ARPOB scope of ARPOB growth as well, but at the same time, addition of cost on account of the existing sites as well as new hospital getting added. So is there a scope for further margin improvement in FY '25? Or we would be, let's say, having bed-related revenue growth, but margin would be a bit stable. Is that the way to understand? Or where is the scope for margin improvement even in FY '25?
No. I mean, there are 2 -- we are mixing 2 things. One is current beds, right? Your current capacity, which was 3,500-odd beds that we have, right? There is [indiscernible] growth and you have a revenue growth, okay. Assuming your revenue growth continues on the same trajectory then you have the cost growth, which would be similar to what happened last year, right? So EBITDA growth in that fashion should -- I mean currently, what is there is it should be that plus because you get some operating leverage as well. So whatever EBITDA growth that you have over here, you won't be having that, right?
Then comes the new hospital. The new hospital will be, let's say, 300 beds. That's about 7% to 8% further capacity. That 300 new beds, one will obviously start with lower ARPOB and negative EBITDA to start. Then the question is when do you break even? You break even in 6 months, you break even in 8 months, you break even in 12 months, you break even in 12 months, then it will have a negative [indiscernible] on the EBITDA. If you break even in 6 months, then 1 year later, it may be a neutral impact to your EBITDA.
So I mean the neutral in still will fully down because if it [indiscernible] the positive EBITDA and you're taking a negligible EBITDA end of [indiscernible] conflating kind of wins happening over here. But my belief is because it's only 8% of the overall listing, it doesn't move the needle too much.
The next question is from the line of Karan Gupta from Marina Capital.
Am I audible?
I couldn't hear you.
The [indiscernible] of your voice is muffled. I would request to use your handset please.
Yes. So basically, the question is related to the international business. So what kind of [indiscernible] we are seeing in the [ deletion ] for the medical tourism. And what's the sense we are taking to that increase the section or maybe increase or improve the quality of our treatment? I mean because I think the question because of maybe [indiscernible] I think once you talk what the U.S. and in -- So what's the traction coming from U.S. and Europe basically we're sharing more on [indiscernible] but [indiscernible] level. So what's your position as this [indiscernible].
We don't get many patients from the U.S. and the U.K. because India is much cheaper, but is sponsored, right? It's sponsored. NHS pays for it. And in the U.S. as government it doesn't matter to sequence somebody has been paying for it. It's never been my case because for the 2 countries. There will only be people from countries where it's helped [indiscernible]
Okay, okay. So when you think about medical tourism, so what's the patients? Where are the patients coming from?
We're getting these patient from 145 countries.
The next question is from the line of Amit Kadam from Canara Robeco Mutual Fund.
Just a couple of things. The swing that we saw in the inpatient volumes this quarter, largely you attributed to the vector-borne business. Just wanted to because we have a very limited understanding like in the last 3 years or so, we haven't seen such kind of large swing because the bed beds for this quarter is negative 1%. So just can you just throw from your past exposure have we had seen such kind of large swing, which could have a material impact on the inpatient volumes and could happen on the bed beds?
No. So what we are saying is last year, same quarter, okay, we had a big influx of patients. We haven't had the same influx this year. Therefore, what we have is a reduction of 1% on the [indiscernible]
So Amit, I don't know If you see the historical brands, you'll find that quarter 2 to quarter 3, there's always a decline. You pick up any computer, any previous reports of quarter 2 to quarter 3, compare them to previous years, you find quarter 3 is always softer, right?
And so minus 1% OBD is very normal. If you compare Apollo, Fortis, Narana, we put up their last year results, obviously, this quarter out, but you'll find that there is a decline in quarter 3 over quarter 2. So there's no exception here, right? So I'm seeing this is the secular trend. You will always find quarter 3 is down to quarter 2 because of the festivities, et cetera.
Diwali, [indiscernible]...
Now the -- in our [indiscernible] one peculiar feature is in last year since in -- especially in Delhi, we had influx of patients in October. Typically, finishes by September. But last year, we had even in October which was a Diwali month, we had daily patients, and the Diwali month occupancy was 76%, right, which is generally unheard of. In a Diwali month, you will have occupancy of less than 70%.
So last year, October was very high occupancy because of India, and that's the reason why you see a drop a bit more sharper, right? Otherwise, it would have been public at. If I really take out the drop in the internal medicine and pediatrics where we get the patient, that drops 12%, right? While you see Y-o-Y, the drop in OBDs only by 1%. But that for specialty which is 22% of the overall bad share, dropped by 12%, right, which is because of the fact that in last year, October, we had many patients.
So I think what we tend to say is that there's nothing operationally wrong in this quarter. It's only when you compare Y-o-Y because of this October influx of patients, there is a bit sharper drop rather than what it should actually look at. So [indiscernible] adjusted, then you find the [indiscernible] went up by Y-on-Y.
Historically, the seasonal business, right? Second quarter and fourth quarter are the strongest quarters in the hospital business. The first quarter and the third quarter of [indiscernible]. First quarter because of [indiscernible] sort of moved up but the third quarter because the revenues come down?
So is that clear number on the...
Yes. No, I was just contesting you at that particular point. I just wanted to know because we have a very limited history because we -- so from the data point, we do not have -- I did not have the insight that whether such kind of -- from seasonalities. When am I talking seasonality, I'm trying to compare Y-o-Y because of some like vector-borne business, can a material impact on the volume growth, Y-o-Y? I can understand how quarter 2 to quarter 3 seasonality works. But I was just seeing in the past, you see whether such kind of events like vector-borne is there could have a material impact on the volume.
100% in there.
Did in this year, right? Because last year, quarter 3 [indiscernible].
That is not an anomaly.
Because much of the [indiscernible] stuff happened.
Why are you even comparing 9 months, 9 months? You're only comparing this quarter to last quarter. On overall annual [indiscernible] not a significant impact based on occupancy.
That I get it, but...
Yes. But yes. I mean, you can't -- if you don't have it have a [indiscernible] season, you can -- I mean, in fact, a drop can be much sharper than this share the 1%.
Okay. And...
Between 1% to 3% fluctuation on both sides, positive as well as negative.
Okay. Got it, sir. And just on the outpatient thing, is it just an outcome of the similar effect that because there were lesser patients visiting because of the -- there was no big...
That's right.
So nothing much to read in this particular thing based on this particular process? Because I earlier seen this outpatient at least growing at mid-teens or kind of thing, but now it's short 3% in this particular nothing much...
I think one thing I'm at doing is you're looking at it year-on-year as an quarter-on-quarter because like I said, we have seasonality in this. So you have the third quarter in any case, weaker than your second quarter. But if you look at it on a Y-to-Y basically, you can attribute it to a number of [indiscernible]
Okay. And just one more final point [indiscernible] So for the current time lines, we should be able to integrate that particular business financials to us by quarter 1 next year, FY '25?
Yes, yes. I mean it depends on when does the happen If the [indiscernible] happens in this month, then sort from the data flowing [indiscernible]. We don't have a choice.
Ladies and gentlemen, this will be the last question for today, which is from the line of Alankar Garude from Kotak Institutional Equities.
Sir, on the question on ARPOB. We have reported a 15% ARPOB CAGR over the last 3 years, and you alluded various factors case mix, international, institutional, insurance, et cetera. Now would it be fair to say that a larger chunk of this improvement can be attributed to an improved case mix?
So Alankar, if you see the -- so you know the elements of ARPOB is, one is the increase in the prices, right, which -- and we've been saying that it can be up to 3%. Then there's an increase in OPDs. You know that OPD revenue increase will improve the ARPOB because you don't consume any beds for those OP revenues. So that typically contributes around 2%. So this make 3% plus 2%, 5%, right? Then you have oncology going, the number of beds that you've seen in oncology growth is outpacing the overall growth. So that oncology happens to be a high-end specialty. So that really adds 2%, 3% to the to ARPOB. And then comes the whole channel with and the case mix. If you take only the oncology out of the case mix, I mean then there is balance specialties and the channel mix. Other than that, it will have been contribute around 6%, 7% fees, and I don't see any reason why it should not going forward. So from my perspective, I think if there's a 9% to 10% growth in ARPOB, that should be reasonable.
But having said that, you have to keep in mind one thing. We are talking about a health care system where there is -- where there is capacity constraint in some manner, right? I mean you've got occupancy levels, which are pretty much at a threshold. When you have that situation, then typically, you'll see a higher uptick on ARPOB compared to vis-a-vis occupancy because you can't move up on occupancy, there isn't so many beds. So more and more patients get sort of pushed to take care, which -- smaller surgeries compared to larger surgeries. So you kind of schedule the largest surgery first. The smaller surgeries are scheduled at or -- given a late date, et cetera. And some of the later date kind of evaporates. So what you see is the quality of work start moving up. At the same time, if you -- if I add a [indiscernible], I could put up beds adjacent to each one of the hospitals, then what you would see is a higher uptick on occupancy and lower existing on ARPOB. There's always interplay between the 2.
That's helpful. Maybe a question linked to that is as we double our headcount over the next 4 to 5 years, would the case mix for the newer beds be as good as our flagship hospitals right from year 1? Or the ramp-up in the case mix would be more [indiscernible]...
No, no. So if you take Shalimar Bagh, right, and Shalimar Bagh, we did a brownfield. So you can look at the expansion again to 85% of it or 90% of it is brownfield, essentially, right? So if you look at Shalimar Bagh where we added the 40% or more beds, and you see our experience over there. Now the bed which got taken up, obviously get taken up more by the institutional business that we are kind of driving up. So therefore, if you see our institutional business, we say [indiscernible] travel year-on-year, it is the same. But if we look at ex-Shalimar Bagh when we are far better in the institutional, institutional overall has come down there. But what it means is even if your operating leverage is so significant, okay, that our EBITDA per bed, which comes out from the incremental basis significantly better.
Yes. So I mean, summary, the ARPOB do in Shalimar Bagh would not be the overall growth will be less than that.
Fair enough.
And in fact, the operating margin even on these beds, okay, higher than the existing beds, yes.
Understood, understood. My second question is, you spoke about the potential of Laknar and Pradesh for us in general earlier. Now when it comes to expansion beyond our already announced plans. You had said earlier that you are looking at some 20, 21 cities for potential expansion. Will we continue to aggressively look out for acquisition opportunities in these 20-odd cities now? Or do our priorities get aligned more towards Pradesh now with the [indiscernible]?
No. So rightly don't get aligned from that standpoint because it's not as if I'm going to get 2 or 3 acquisitions in a baseline right now. Even if you have a strategy of looking at building it out, that is going to still take some time, right? It takes years. We are looking at deploying our balance sheet today. So -- and we have the wells to do it. For us to add 1, 2, 3, 4 hospitals in a space of 1 to 2 years, et cetera, it's not a big thing because rest of the things that we're doing is essentially brownfield in any case. I mean it doesn't tax me more. I mean, it takes me as much effort to do expansion on Shalimar Bagh, operating Shalimar Bagh, an similarly, wherever we can [indiscernible] both from [indiscernible]
Question for today [indiscernible]
Thank you all for being on the call. Thank you for the third quarter, and we are looking forward to a robust and a strong Q4. As usually is the case, because we see [indiscernible]. Thank you so much.
Thank you, members of the management. Ladies and gentlemen, on behalf of Max Healthcare Institute Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines. Thank you.
Thank you.